Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $29.62

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $29.6250.

A number of research firms have weighed in on FDMT. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $15.56 on Monday. The company has a market cap of $859.53 million, a P/E ratio of -5.92 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The business’s 50 day moving average price is $12.00 and its 200-day moving average price is $10.26. 4D Molecular Therapeutics has a fifty-two week low of $5.97 and a fifty-two week high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. Sell-side analysts predict that 4D Molecular Therapeutics will post -4.09 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Kirn sold 114,746 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 200,496 shares of company stock worth $2,240,244. Insiders own 7.90% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at $39,000. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics in the 3rd quarter worth about $41,000. AQR Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the 1st quarter worth about $46,000. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after buying an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at about $48,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.